Month: January 2022

SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate in a fireside chat at the… Click here to view original post… […]

SAN DIEGO: SAN DIEGO, Jan. 5, 2022 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Chief Executive Officer, Robert E. Hoffman will present at the H.C. Wainwright Bioconnect 2022 Virtual Conference, which is taking… Click here to view original post… […]

SAN DIEGO: SAN DIEGO, Jan. 5, 2022 /PRNewswire/ — Explora BioLabs, the nation’s largest provider of preclinical vivarium research space, recently added a new attending veterinarian to oversee their national network of AAALAC accredited in vivo facilities for preclinical rodent research needs. Dr. Kathy Hardcastle has over 16 years of… Click here to view original post… […]

SAN DIEGO: SAN DIEGO, Jan. 5, 2022 /PRNewswire/ — Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will present next week at the H.C. Wainwright Bioconnect Conference and the Biotech… Click here to view original post… […]

CARLSBAD, Calif.: CARLSBAD, Calif., Jan. 5, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the virtual 40th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. ET on Wednesday, January 12, 2022. A live webcast… Click here to view original post… […]

NEW YORK and SAN DIEGO: NEW YORK and SAN DIEGO, Jan. 5, 2022 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for patients with unmet needs and EpicentRx, Inc. ("EpicentRx"), a San Diego-based clinical cancer immunotherapy company today… Click here to view original post… […]

SAN DIEGO–(BUSINESS WIRE)–ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA-targeting therapeutics, today announced the appointment of Hubert C. Chen, M.D. as Chief Medical Officer. “We are delighted to have Hubert join ADARx at such a pivotal moment in our company’s growth,” said Dr. Zhen Li, President and Chief Executive officer… Click here to view original post… […]

SAN DIEGO: SAN DIEGO, Jan. 4, 2022 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced initial results from Part 3 (combination dose escalation) of the 4-part Phase 1 trial of INBRX-106, a novel hexavalent OX40 agonist,… Click here to view original post… […]

SAN DIEGO: SAN DIEGO, Jan. 4, 2022 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the Company will present at the J.P. Morgan 40th Annual Virtual Healthcare Conference, on Monday, January 10, 2022. David Meek, chief executive officer, will make a formal presentation… Click here to view original post… […]

LA JOLLA—The discovery of insulin 100 years ago opened a door that would lead to life and hope for millions of people with diabetes. Ever since then, insulin, produced in the pancreas, has been considered the primary means of treating conditions characterized by high blood sugar (glucose), such as diabetes…. Click here to view original post… […]

SAN DIEGO: SAN DIEGO, Jan. 4, 2022 /PRNewswire/ — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present at the H.C. Wainwright BIOCONNECT Virtual Conference. The pre-recorded webcast will be available for on-demand viewing beginning Monday, January 10,… Click here to view original post… […]

SAN DIEGO–(BUSINESS WIRE)– #ASO–John Maraganore to chair n-Lorem’s Advisory Council that focuses on exploring fundraising and raising awareness of n-Lorem and its mission. Click here to view original post… […]

SAN DIEGO: SAN DIEGO, Jan. 4, 2022 /PRNewswire/ — Locanabio, Inc., a genetic medicines company developing therapeutics for patients with severe neuromuscular, neurodegenerative and retinal diseases, today announced that Jim Burns, PhD, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022… Click here to view original post… […]

SAN DIEGO: SAN DIEGO, Jan. 4, 2022 /PRNewswire/ — The Deerborne Group, a global boutique management consulting firm, today announced they will attend the 40th Annual J.P. Morgan Healthcare Conference events held virtually from January 10th to 13th, 2022. Their Managing Partner, Jeffrey Jones, is available virtually throughout the week… Click here to view original post… […]

SAN DIEGO–(BUSINESS WIRE)– #genetic–Ray Therapeutics Closes $6M Seed Financing to Advance Novel Optogenetics Platform to Treat Blinding Diseases. Click here to view original post… […]

LA JOLLA, Calif.–(BUSINESS WIRE)—- $EQ–Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced publication of a manuscript featured on the front cover of the Journal of Clinical Investigation (www.jci.org/this-month), confirming the role of T cells… Click here to view original post… […]

SAN DIEGO: SAN DIEGO, Jan. 4, 2022 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will present virtually at the 40th Annual J.P. Morgan Health Care Conference on Monday, January 10, 2022 at 7:30 a.m. PT/ 10:30 a.m. ET. The… Click here to view original post… […]